JFLLIFE

JFL Life Sciences Share Price

 

 

Start SIP in JFLLIFE

Start SIP
JFL Life Sciences live price: ₹8.95. It opened at ₹9 vs previous close ₹9; intraday high/low: ₹9/₹9. The 50 & 200 DMA stand at ₹10.65/₹13.55.

JFL Life Sciences Performance

  • Today's Low
  • ₹9
  • Today's High
  • ₹9
  • 52 Week Low
  • ₹9
  • 52 Week High
  • ₹21
  • Open Price₹9
  • Previous Close₹9
  • Volume6,000
  • 50 DMA₹10.65
  • 100 DMA₹11.73
  • 200 DMA₹13.55

Investment Returns

  • Over 1 Month -18.64%
  • Over 3 Month -28.4%
  • Over 6 Month -30.89%
  • Over 1 Year -48.71%

Smart Investing Starts Here Start SIP with JFL Life Sciences for Steady Growth!

Invest Now

JFL Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.2
  • PEG Ratio
  • -0.9
  • Market Cap Cr
  • 59
  • P/B Ratio
  • 0.8
  • Average True Range
  • 0.46
  • EPS
  • 0.73
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.43
  • RSI
  • 35.31
  • MFI
  • 30.93

JFL Life Sciences Financials

JFL Life Sciences Technicals

EMA & SMA

Current Price
₹8.95
+ 0.4 (4.68%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹9.84
  • 50 Day
  • ₹10.65
  • 100 Day
  • ₹11.73
  • 200 Day
  • ₹13.55

Resistance and Support

8.95 Pivot Speed
  • R3 8.95
  • R2 8.95
  • R1 8.95
  • S1 8.95
  • S2 8.95
  • S3 8.95

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Jfl Life Sciences has an operating revenue of Rs. 80.06 Cr. on a trailing 12-month basis. An annual revenue growth of 74% is outstanding, Pre-tax margin of 7% is okay, ROE of 10% is good. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 137 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

JFL Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-03-04 Others To consider other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:1 @ par.
2026-01-29 Quarterly Results & Others To consider other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:1 @ par.
2025-11-11 Quarterly Results & Others To consider other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:1 @ par.
2025-09-01 Others To consider other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:1 @ par.
2025-08-11 Quarterly Results & Others To consider other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:1 @ par.
Date Purpose Remarks
2024-09-24 Bonus Rs.0.00 issue in the ratio of 2:1 of Rs. 10/-.

JFL Life Sciences F&O

JFL Life Sciences Shareholding Pattern

67.47%
28.54%
3.99%

JFL Life Sciences FAQs

JFL Life Sciences share price is ₹8 As on 02 April, 2026 | 03:57

The Market Cap of JFL Life Sciences is ₹59.1 Cr As on 02 April, 2026 | 03:57

The P/E ratio of JFL Life Sciences is 14.2 As on 02 April, 2026 | 03:57

The PB ratio of JFL Life Sciences is 0.8 As on 02 April, 2026 | 03:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23